Methods for treating pain by inhibition of the SCN9A channel
AssigneeXenon Pharmaceuticals Inc.
InventorsMarcia L. MacDonald, Mark E. Samuels, Robin Sherrington, Yigal P. Goldberg
Life of this patent
Estimating the term…
Abstract
The present invention relates to the discovery that mutations in SCN9A are causative of Congenital Indifference to Pain (CIP) in humans. The invention also relates to methods of utilizing the SCN9A gene and expression products thereof for the screening and identification of therapeutic agents, including small organic compounds, which are selective for SCN9A, and are useful in the treatment of pain and other disorders. The invention also relates to methods of using these compounds to treat or otherwise ameliorate such disorders.
Claims10
A method for reducing pain in a mammal afflicted therewith, comprising administering to said mammal an effective amount of an agent that selectively decreases SCN9A-mediated ion flux activity in said mammal.
Dependencies are inferred from the claim text.